CompletedPhase 3

MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy

South Korea180 participantsStarted 2018-04-09

Plain-language summary

To evaluate the efficacy and safety of MEDITOXIN in subjects with benign masseteric hypertrophy compared with placebo

Who can participate

Age range20 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * subject who aged 20 to less than 65 years * subject with benign masseteric hypertrophy Exclusion Criteria: * subject not appropriate for participating in this study according to the investigator's opinion * subject with known an anaphylactic response to BoNT/A and other involved ingredients of Investigational product

What they're measuring

changes in the thickness of the masseter muscle during maximum clenching measured using ultrasound at week 12 from baseline

Timeframe: 12 week follow-up visit

Trial details

NCT IDNCT03452345

SponsorMedy-Tox

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-01-31

View on ClinicalTrials.gov More Masseter Muscle Hypertrophy trials